UPCC 34418: A phase Ib multicenter study to determine the safety and tolerability of tisagenlecleucel in combination with ibrutinib in adult patients with relapsed and/or refractory diffuse large B-cell lymphoma
Enrolling By Invitation
99 years or below
All
Phase
1
10 participants needed
1 Location
Brief description of study
The purpose of the study is to find out if an engineered T-cell therapy (tisagenlecleucel) in combination with ibrutinib is safe and tolerable for people with relapsed and/or refractory diffuse large B-cell lymphoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: ['Diffuse Large B-cell Lymphoma']
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 831439
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
